Cytosorbents Corporation (CTSO): Price and Financial Metrics
CTSO Price/Volume Stats
| Current price | $0.88 | 52-week high | $4.29 |
| Prev. close | $0.81 | 52-week low | $0.78 |
| Day low | $0.80 | Volume | 108,100 |
| Day high | $0.92 | Avg. volume | 156,206 |
| 50-day MA | $0.94 | Dividend yield | N/A |
| 200-day MA | $1.67 | Market Cap | 47.72M |
CTSO Stock Price Chart Interactive Chart >
Cytosorbents Corporation (CTSO) Company Bio
CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent polymer technology. The company was founded in 1997 and is based in Monmouth Junction, New Jersey.
Latest CTSO News From Around the Web
Below are the latest news stories about CYTOSORBENTS CORP that investors may wish to consider to help them evaluate CTSO as an investment opportunity.
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board RecommendationPRINCETON, N.J., Dec. 28, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announces an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board (“DSMB”) analysis for the pivotal U.S. and Canadian STAR-T (Safe and |
Insider Spends US$100k Buying More Shares In CytosorbentsInvestors who take an interest in Cytosorbents Corporation ( NASDAQ:CTSO ) should definitely note that the CEO... |
Insider Buying: CEO Phillip Chan Acquires 75,188 Shares of CytoSorbents Corp (CTSO)Recent insider trading activity has caught the attention of investors as Phillip Chan, CEO of CytoSorbents Corp, made a significant purchase of company shares. |
CytoSorbents Announces Closing of $10.3 Million Registered Direct OfferingCompany insiders participated in the transaction with $435,000 of investmentPRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announces the closing of its previously announced registered direct offering for the sale by the Company directly to investors of an aggregate of |
CTSO: CytoSorbents reports 3rd quarter 2023 financial and operating results which showed strong product revenue growth and an improved cost structure.By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT CytoSorbents (NASDAQ:CTSO) reported 3rd quarter 2023 results on November 9th which showed strong product revenue growth. 3rd quarter product revenues increased 20% to $7.8 million and grant income decreased 35.9%. The increase in the Euro to U.S. dollar exchange rate positively impacted product sales by approximately $508,000. The |
CTSO Price Returns
| 1-mo | -3.01% |
| 3-mo | -0.36% |
| 6-mo | -42.48% |
| 1-year | -67.41% |
| 3-year | -90.33% |
| 5-year | -88.34% |
| YTD | -20.72% |
| 2023 | -28.39% |
| 2022 | -63.01% |
| 2021 | -47.43% |
| 2020 | 107.01% |
| 2019 | -52.35% |
Continue Researching CTSO
Want to see what other sources are saying about Cytosorbents Corp's financials and stock price? Try the links below:Cytosorbents Corp (CTSO) Stock Price | Nasdaq
Cytosorbents Corp (CTSO) Stock Quote, History and News - Yahoo Finance
Cytosorbents Corp (CTSO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...